Table 2.

Current clinical trials “Enrolling” COVID‐19 patients for stem cells‐based therapies

Trial number/identification	Condition or disease	Cell type used as an intervention	Phase
NCT04348435	COVID‐19	Allogeneic AdMSCs	II
NCT04382547	COVID‐19, viral pneumonia	Allogenic‐pooled‐olfactory mucosa‐derived MSCs	I/II
NCT04349631	COVID‐19	AT‐MSCs (AdMSCs; autologous)	II

Abbreviations: AdMSC, adipose‐derived mesenchymal stem cell; AT‐MSC, adipose tissue‐derived mesenchymal stem cell; COVID‐19, novel coronavirus disease; MSC, mesenchymal stem cell.